Additionally, inhibitors of EGFR or EPHA2, or agents that modulate WNT5A signaling, may therefore represent potential adjuvant approaches to improve therapeutic efficacy and patient outcomes in the melanoma subtypes with heightened epidermal signaling activity, as in the identified Cluster B. Nevertheless, more targeted studies would be needed to confirm such observations. The gene discussed is EGFR; the disease is melanoma.